VYNE Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 22:00):

Stats
Dagens volum	15 849.00
Gjennomsnittsvolum	106 139
Markedsverdi	35.25M
EPS	$0 ( 2024-03-14 )
Neste inntjeningsdato	( $-0.240 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.920
ATR14	$0.0240 (0.97%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Zeronda Tyler	Sell	94	Common Stock
2024-04-01	Stuart Iain	Sell	157	Common Stock
2024-04-01	Harsch Mutya	Sell	161	Common Stock
2024-04-01	Domzalski David	Sell	1 004	Common Stock
2024-01-01	Zeronda Tyler	Buy	62 500	Common Stock

INSIDER POWER
-56.79
Last 99 transactions
Buy: 3 356 313 \| Sell: 7 897 303

Volum Korrelasjon

Lang: 0.36 (neutral)

Kort: -0.34 (neutral)

Signal:(51.533) Neutral

VYNE Therapeutics Inc. Korrelasjon

10 Mest positive korrelasjoner
ALBO	0.962
CMPI	0.962
OCSL	0.934
PALT	0.913
IRMD	0.911
PLRX	0.91
MLAC	0.905
ANDE	0.905
NATI	0.903
DRNA	0.902

10 Mest negative korrelasjoner
CFV	-0.951
AKAM	-0.888
BNIXU	-0.882
GMII	-0.88
TUEM	-0.874
EAR	-0.85
SHLD	-0.845
TRMK	-0.84
DTSS	-0.838
VIVE	-0.837

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

VYNE Therapeutics Inc. Korrelasjon - Valuta/Råvare

0.49
( neutral )

0.50
( neutral )

0.00
( neutral )

0.37
( neutral )

-0.29
( neutral )

0.17
( neutral )

VYNE Therapeutics Inc. Økonomi

Annual	2023
Omsetning:	$424 000
Bruttogevinst:	$424 000 (100.00 %)
EPS:	$-2.77

FY	2023
Omsetning:	$424 000
Bruttogevinst:	$424 000 (100.00 %)
EPS:	$-2.77

FY	2022
Omsetning:	$477 000
Bruttogevinst:	$477 000 (100.00 %)
EPS:	$-10.65

FY	2021
Omsetning:	$14.76M
Bruttogevinst:	$11.41M (77.31 %)
EPS:	$-1.420

Financial Reports:

No articles found.

VYNE Therapeutics Inc.

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.